Literature DB >> 25742194

Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging.

Robert J McDonald1, Jennifer S McDonald, David F Kallmes, Mark E Jentoft, David L Murray, Kent R Thielen, Eric E Williamson, Laurence J Eckel.   

Abstract

PURPOSE: To determine if repeated intravenous exposures to gadolinium-based contrast agents (GBCAs) are associated with neuronal tissue deposition.
MATERIALS AND METHODS: In this institutional review board-approved single-center study, signal intensities from T1-weighted magnetic resonance (MR) images and postmortem neuronal tissue samples from 13 patients who underwent at least four GBCA-enhanced brain MR examinations between 2000 and 2014 (contrast group) were compared with those from 10 patients who did not receive GBCA (control group). Antemortem consent was obtained from all study participants. Neuronal tissues from the dentate nuclei, pons, globus pallidus, and thalamus of these 23 deceased patients were harvested and analyzed with inductively coupled plasma mass spectrometry (ICP-MS), transmission electron microscopy, and light microscopy to quantify, localize, and assess the effects of gadolinium deposition. Associations between cumulative gadolinium dose, changes in T1-weighted MR signal intensity, and ICP-MS-derived tissue gadolinium concentrations were examined by using the Spearman rank correlation coefficient (ρ).
RESULTS: Compared with neuronal tissues of control patients, all of which demonstrated undetectable levels of gadolinium, neuronal tissues of patients from the contrast group contained 0.1-58.8 μg gadolinium per gram of tissue, in a significant dose-dependent relationship that correlated with signal intensity changes on precontrast T1-weighted MR images (ρ = 0.49-0.93). All patients in the contrast group had relatively normal renal function at the time of MR examination. Gadolinium deposition in the capillary endothelium and neural interstitium was observed only in the contrast group.
CONCLUSION: Intravenous GBCA exposure is associated with neuronal tissue deposition in the setting of relatively normal renal function. Additional studies are needed to investigate the clinical significance of these findings and the generalizability to other GBCAs. Online supplemental material is available for this article. RSNA, 2015

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25742194     DOI: 10.1148/radiol.15150025

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  377 in total

Review 1.  The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.

Authors:  Mariane Le Fur; Peter Caravan
Journal:  Metallomics       Date:  2019-02-20       Impact factor: 4.526

2.  Reply to Letter to the Editor re: Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: Correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol.

Authors:  Dragan A Stojanov
Journal:  Eur Radiol       Date:  2015-09-21       Impact factor: 5.315

3.  Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

Authors:  Christopher Klenk; Rakhee Gawande; Vy Thao Tran; Jennifer Trinh Leung; Kevin Chi; Daniel Owen; Sandra Luna-Fineman; Kathleen M Sakamoto; Alex McMillan; Andy Quon; Heike E Daldrup-Link
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

4.  How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach.

Authors:  Anne M Muehe; Ashok J Theruvath; Lillian Lai; Maryam Aghighi; Andrew Quon; Samantha J Holdsworth; Jia Wang; Sandra Luna-Fineman; Neyssa Marina; Ranjana Advani; Jarrett Rosenberg; Heike E Daldrup-Link
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

Review 5.  Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.

Authors:  Kerry A Layne; Paul I Dargan; John R H Archer; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2018-08-17       Impact factor: 4.335

6.  A nephrotoxicity-free, iron-based contrast agent for magnetic resonance imaging of tumors.

Authors:  Xiangdong Xue; Ruonan Bo; Haijing Qu; Bei Jia; Wenwu Xiao; Ye Yuan; Natalia Vapniarsky; Aaron Lindstrom; Hao Wu; Dalin Zhang; Longmeng Li; Marina Ricci; Zhao Ma; Zheng Zhu; Tzu-Yin Lin; Angelique Y Louie; Yuanpei Li
Journal:  Biomaterials       Date:  2020-07-15       Impact factor: 12.479

Review 7.  Is MRI imaging in pediatric age totally safe? A critical reprisal.

Authors:  Sergio Salerno; Claudio Granata; Marco Trapenese; Vittorio Cannata; Davide Curione; Maria Camilla Rossi Espagnet; Andrea Magistrelli; Paolo Tomà
Journal:  Radiol Med       Date:  2018-05-03       Impact factor: 3.469

8.  Self-gated 4D multiphase, steady-state imaging with contrast enhancement (MUSIC) using rotating cartesian K-space (ROCK): Validation in children with congenital heart disease.

Authors:  Fei Han; Ziwu Zhou; Eric Han; Yu Gao; Kim-Lien Nguyen; J Paul Finn; Peng Hu
Journal:  Magn Reson Med       Date:  2016-08-16       Impact factor: 4.668

9.  The Effects of Acetazolamide on the Evaluation of Cerebral Hemodynamics and Functional Connectivity Using Blood Oxygen Level-Dependent MR Imaging in Patients with Chronic Steno-Occlusive Disease of the Anterior Circulation.

Authors:  J Wu; S Dehkharghani; F Nahab; J Allen; D Qiu
Journal:  AJNR Am J Neuroradiol       Date:  2016-10-06       Impact factor: 3.825

Review 10.  Gadolinium-based contrast agents in children.

Authors:  Michael N Rozenfeld; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2018-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.